Metastatic dissemination of 3LL variants after treatment with monoclonal antibody to a tumor-associated antigen

Ada Sacchi, Stephen Kennel, Pier Giorgio Natali, Giulio Tibursi, Cinzia Apollonj Ghetti

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Two tumor lines derived from 3LL (Lewis lung carcinoma) endowed with different metastatic potential and stable for their metastatic phenotype during serial in vivo passages, have been analysed for growth and dissemination following treatment with a monoclonal antibody. We have used a recently developed MoAb 135-13C to a tumor-associated antigen of murine lung carcinoma having an apparent molecular weight of 180000 (TSP-180). The metastatic dissemination of the 3LL variants before and after treatment with the MoAb has been correlated with the expression on the cell surface of the MHC antigens (Db, Kb) and of the TSP-180 protein. The results of this study indicate that cell with high TSP-180 protein expression and MHC antigen expression have the greatest metastatic potential. Administration of MoAb 135-13C to tumor-bearing mice or i.v. injection of cells preincubated with the MoAb 135-13C increase the dissemination capacity of the variant endowed with lower metastatic potential while inducing a reverse effect on the high metastatic one. Studies on the MHC expression demonstrate that MoAb 135-13C treatment induces changes in the Db and Kb expression at level of secondary neoplasms. The results are discussed in view of the importance of the use of the metastatic variants to study therapeutic effect of specific targeting agent.

Original languageEnglish (US)
Pages (from-to)245-257
Number of pages13
JournalClinical & Experimental Metastasis
Volume5
Issue number3
DOIs
StatePublished - Jul 1 1987

Fingerprint

Integrin alpha6beta4
Neoplasm Antigens
Monoclonal Antibodies
Lewis Lung Carcinoma
Neoplasms
Therapeutic Uses
Surface Antigens
Proteins
Therapeutics
Molecular Weight
Carcinoma
Phenotype
Antigens
Lung
Injections
Growth

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Metastatic dissemination of 3LL variants after treatment with monoclonal antibody to a tumor-associated antigen. / Sacchi, Ada; Kennel, Stephen; Natali, Pier Giorgio; Tibursi, Giulio; Ghetti, Cinzia Apollonj.

In: Clinical & Experimental Metastasis, Vol. 5, No. 3, 01.07.1987, p. 245-257.

Research output: Contribution to journalArticle

Sacchi, Ada ; Kennel, Stephen ; Natali, Pier Giorgio ; Tibursi, Giulio ; Ghetti, Cinzia Apollonj. / Metastatic dissemination of 3LL variants after treatment with monoclonal antibody to a tumor-associated antigen. In: Clinical & Experimental Metastasis. 1987 ; Vol. 5, No. 3. pp. 245-257.
@article{8fe0a1988463405fa092617d2031f09f,
title = "Metastatic dissemination of 3LL variants after treatment with monoclonal antibody to a tumor-associated antigen",
abstract = "Two tumor lines derived from 3LL (Lewis lung carcinoma) endowed with different metastatic potential and stable for their metastatic phenotype during serial in vivo passages, have been analysed for growth and dissemination following treatment with a monoclonal antibody. We have used a recently developed MoAb 135-13C to a tumor-associated antigen of murine lung carcinoma having an apparent molecular weight of 180000 (TSP-180). The metastatic dissemination of the 3LL variants before and after treatment with the MoAb has been correlated with the expression on the cell surface of the MHC antigens (Db, Kb) and of the TSP-180 protein. The results of this study indicate that cell with high TSP-180 protein expression and MHC antigen expression have the greatest metastatic potential. Administration of MoAb 135-13C to tumor-bearing mice or i.v. injection of cells preincubated with the MoAb 135-13C increase the dissemination capacity of the variant endowed with lower metastatic potential while inducing a reverse effect on the high metastatic one. Studies on the MHC expression demonstrate that MoAb 135-13C treatment induces changes in the Db and Kb expression at level of secondary neoplasms. The results are discussed in view of the importance of the use of the metastatic variants to study therapeutic effect of specific targeting agent.",
author = "Ada Sacchi and Stephen Kennel and Natali, {Pier Giorgio} and Giulio Tibursi and Ghetti, {Cinzia Apollonj}",
year = "1987",
month = "7",
day = "1",
doi = "10.1007/BF00124306",
language = "English (US)",
volume = "5",
pages = "245--257",
journal = "Clinical and Experimental Metastasis",
issn = "0262-0898",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Metastatic dissemination of 3LL variants after treatment with monoclonal antibody to a tumor-associated antigen

AU - Sacchi, Ada

AU - Kennel, Stephen

AU - Natali, Pier Giorgio

AU - Tibursi, Giulio

AU - Ghetti, Cinzia Apollonj

PY - 1987/7/1

Y1 - 1987/7/1

N2 - Two tumor lines derived from 3LL (Lewis lung carcinoma) endowed with different metastatic potential and stable for their metastatic phenotype during serial in vivo passages, have been analysed for growth and dissemination following treatment with a monoclonal antibody. We have used a recently developed MoAb 135-13C to a tumor-associated antigen of murine lung carcinoma having an apparent molecular weight of 180000 (TSP-180). The metastatic dissemination of the 3LL variants before and after treatment with the MoAb has been correlated with the expression on the cell surface of the MHC antigens (Db, Kb) and of the TSP-180 protein. The results of this study indicate that cell with high TSP-180 protein expression and MHC antigen expression have the greatest metastatic potential. Administration of MoAb 135-13C to tumor-bearing mice or i.v. injection of cells preincubated with the MoAb 135-13C increase the dissemination capacity of the variant endowed with lower metastatic potential while inducing a reverse effect on the high metastatic one. Studies on the MHC expression demonstrate that MoAb 135-13C treatment induces changes in the Db and Kb expression at level of secondary neoplasms. The results are discussed in view of the importance of the use of the metastatic variants to study therapeutic effect of specific targeting agent.

AB - Two tumor lines derived from 3LL (Lewis lung carcinoma) endowed with different metastatic potential and stable for their metastatic phenotype during serial in vivo passages, have been analysed for growth and dissemination following treatment with a monoclonal antibody. We have used a recently developed MoAb 135-13C to a tumor-associated antigen of murine lung carcinoma having an apparent molecular weight of 180000 (TSP-180). The metastatic dissemination of the 3LL variants before and after treatment with the MoAb has been correlated with the expression on the cell surface of the MHC antigens (Db, Kb) and of the TSP-180 protein. The results of this study indicate that cell with high TSP-180 protein expression and MHC antigen expression have the greatest metastatic potential. Administration of MoAb 135-13C to tumor-bearing mice or i.v. injection of cells preincubated with the MoAb 135-13C increase the dissemination capacity of the variant endowed with lower metastatic potential while inducing a reverse effect on the high metastatic one. Studies on the MHC expression demonstrate that MoAb 135-13C treatment induces changes in the Db and Kb expression at level of secondary neoplasms. The results are discussed in view of the importance of the use of the metastatic variants to study therapeutic effect of specific targeting agent.

UR - http://www.scopus.com/inward/record.url?scp=0023254063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023254063&partnerID=8YFLogxK

U2 - 10.1007/BF00124306

DO - 10.1007/BF00124306

M3 - Article

C2 - 3652554

AN - SCOPUS:0023254063

VL - 5

SP - 245

EP - 257

JO - Clinical and Experimental Metastasis

JF - Clinical and Experimental Metastasis

SN - 0262-0898

IS - 3

ER -